Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.
Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Bone Marrow Transplant. 2019 Aug;54(8):1254-1265. doi: 10.1038/s41409-018-0401-4. Epub 2018 Dec 13.
We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had ≥1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.
我们分析了 CIBMTR 数据,以评估在异基因造血干细胞移植(alloHCT)后 100 天内发生的细菌血流感染(BSI)的非复发死亡率(NRM)发生率及其与总生存率(OS)的关系,BSI 分为两个阶段:植入前/植入期(BSI 早期阶段,BSI-VEP)和植入后(BSI 发生在植入后 2 周至第 100 天,早期晚期阶段,BSI-LEP)。在 7128 例 alloHCT 患者中,有 2656 例(37%)在 100 天内发生了≥1 次 BSI。BSI-VEP、BSI-LEP 和 BSI-两者分别构成总 BSI 的 56%(n=1492)、31%(n=824)和 13%(n=340)。自 2009 年以来,我们观察到 BSI 发生率从 2009 年到 2012 年逐渐下降(61-48%)。BSI-VEP 患者更可能接受含全身照射(TBI)的清髓性预处理方案。任何 BSI 患者的 NRM 均显著高于无 BSI 患者(BSI-VEP 的 RR 为 1.82,95%CI 为 1.63-2.04;BSI-LEP 的 RR 为 2.46,95%CI 为 2.05-2.96;BSI-两者的 RR 为 2.29,95%CI 为 1.87-2.81)。与无 BSI 患者相比,任何 BSI 患者的 OS 均显著降低(BSI-VEP 的 RR 为 1.36,95%CI 为 1.26-1.47;BSI-LEP 的 RR 为 1.83,95%CI 为 1.58-2.12;BSI-两者的 RR 为 1.66,95%CI 为 1.43-1.94)。alloHCT 后 100 天内的 BSIs 很常见,仍然是死亡的危险因素。